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EDITORIAL
Fat-kidneyed
Although the Bard may have recognized the existence enzyme found mainly in muscle and adipose tissue. LpL
activity is reduced in both uremia and nephrosis, provid-of renal consequences of hyperlipidemia [1], the possible
participation of lipids in renal disease progression was ing a partial explanation for the dyslipidemia that charac-
first suggested by Virchow more than three centuries later terizes these states. Reduced LpL activity is multifacto-
[2]. Interest in the nephrotoxic consequences of hyperlip- rial. The apolipoprotein C11 is an essential cofactor for
idemia was rekindled two decades ago [3], and there is LpL, and its concentration is reduced in nephrotic
now robust evidence that in certain experimental situa- VLDL, possibly due to urinary loss of C11 as a constit-
tions lipid derangements and their manipulation alter uent of high-density lipoprotein. On the other hand, re-
the natural history of progressive chronic renal disease tention of lipase inhibitors, and the enrichment of VLDL
[4]. However, data supporting a role for dyslipidemia in with C111 [which inhibits hydrolysis by LpL and apolipo-
the progression of human renal disease are less clear- protein E (apoE)-mediated lipoprotein clearance] have
cut. In a recent meta-analysis of 13 prospective con- been implicated in reduced LpL activity in uremia. The
trolled trials involving almost 400 patients, antilipemic consequences of reduced LpL activity are not limited
treatment [mainly inhibitors of 3-hydroxy-3-methylglu- to impaired triglyceride hydrolysis and reduced cellular
taryl coenzyme A (HMG CoA) reductase] was associ- uptake of fatty acids. LpL also facilitates the binding
ated with a reduction in the rate of decline of glomerular and uptake of triglyceride-rich intact lipoproteins such
filtration rate (GFR) by 0.16 mL/min/month [5], an effect as VLDL.
comparable to that of angiotensin-converting enzyme Various lipoproteins, including VLDL, VLDL rem-
(ACE) inhibitors and superior to that of dietary protein nants, LDL and oxidized lipoproteins [9] have been
restriction. Yet this meta-analysis has been criticized for shown to induce in vitro mesangial proliferation, a recog-
its inclusion of non-randomized and heterogenous trials nized precursor of glomerulosclerosis. In this issue of
[6], and skepticism about the true role of lipids in pro- Kidney International, Stevenson et al. have added an-
gression of chronic renal disease remains healthy. other piece to the puzzle of dyslipidemic mesangial injury
Parallels have been drawn between atherosclerosis [10]. They showed that VLDL, purified from hyperlipid-
and focal glomerulosclerosis [7], so it is not surprising emic obese Zucker rats, bound to cultured rat mesangial
that exploration of mesangial consequences of hyperlip- cells to cause cell proliferation and transcription of plate-
idemia have focused on the atherogenic moieties, choles- let-derived growth factor (PDGF). Based on observa-
terol, low-density lipoprotein (LDL), and oxidized LDL. tions in other cell types and with other lipoproteins,
This focus is vindicated by the profile of nephrotic dyslip- it is likely that transcription of other glomerulopathic
idemia, characterized as it is by hypercholesterolemia cytokines would also be induced by VLDL. The VLDL
and elevated LDL. A shift in interest toward hypertri- concentrations necessary for its pro-proliferative effect
glyceridemia can be defended, however, by its athero- were in fact lower than those described by other investi-
genic potential (albeit more modest), its proven role in gators for the same activity of LDL. The binding of
renal progression in some experimental models, by its VLDL was facilitated by LpL (derived from fresh raw
status as the primary lipid abnormality of uremia, and bovine milk), as were its effects on cell proliferation and
as a common companion of nephrotic hypercholesterol- gene expression. For the proliferation and transcription
emia. studies denatured LpL was used to obviate separate
Very low-density lipoprotein (VLDL) contains 60% downstream effects of catalytically active LpL and its
triglyceride by mass, and its concentration is elevated hydrolytic products (fatty acids). Moreover, catalytically
in uremic and nephrotic serum. In both circumstances inactive LpL alone was pro-proliferative and increased
hypertriglyceridemia arises because of reduced metabo- PDGF expression, an effect that had only been shown
lism [8]. VLDL (and other lipoproteins) are hydrolyzed before in monocytes using intact LpL. Heparanase, pre-
by lipoprotein lipase (LpL), an endothelial cell surface sumably due to its interference with cell-surface proteo-
glycans, inhibited LpL-induced amplification of VLDL
binding, mesangial cell proliferation, and PDGF tran-Key words: hyperlipidemia, dyslipidemia, low-density lipoprotein, very
low-density lipoprotein, lipoprotein lipase, glomerulosclerosis. scription, but did not influence the independent effects
of VLDL and LpL on these processes. Thus, in mesangialÓ 2001 by the International Society of Nephrology
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cells, as in other cells, LpL has potent actions that are was synergistic [10]. Thus, antilipidemic agents could
be predicted to have an adverse or favorable effect ondependent on and independent of its hydrolytic products.
How relevant are these findings to human renal dis- VLDL-induced mesangial proliferation and ultimate
sclerosis, depending on the predominance of effects ofease? Certainly the dyslipidemic milieu of uremia would
at least partially favor such a role for VLDL and LpL, the lipoprotein (VLDL) or its enzyme (LpL). Moreover,
the relative importance of VLDL, LpL, and triglycerideand they accord well with an attractive if not well-sub-
stantiated hypothesis for induction of glomerulosclerosis versus LDL and cholesterol in causing glomerular and
mesangial injury remains uncertain.in humans with progressive renal disease. However,
there are several caveats in these observations. The At this stage it is not possible to ascribe any more than
a permissive role to hyperlipidemia and, in particular,VLDL used in this study was derived from the obese
Zucker rat, a model characterized by hyperlipidemia, hypertriglyceridemia in the progressive nature of chronic
renal failure. Many more studies, both human and exper-mesangial expansion and hypercellularity, glomerular
macrophage infiltration, lipid deposits, and ultimately imental, are necessary before we will know the true
meaning and importance of being “fat-kidneyed” [1].glomerulosclerosis. Unlike normal rat VLDL, obese
Zucker VLDL is rich in cholesterol as well as triglycer-
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